Favorable outcomes of metformin on coronary microvasculature in experimental diabetic cardiomyopathy

Although metformin is widely prescribed in diabetes, its use with associated cardiac dysfunction remains debatable. In the current study, we investigated the effect of metformin on coronary microvasculature in experimental diabetic cardiomyopathy (DCM) induced by streptozotocin. Administration of me...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular histology 2018-12, Vol.49 (6), p.639-649
Main Authors: Abdel-Hamid, Ahmed A. M., Firgany, Alaa El-Din L.
Format: Article
Language:English
Subjects:
Animals
Antidiabetics
Biomedical and Life Sciences
Biomedicine
Cardiomyocytes
Cardiomyopathy
Cell Biology
Collagen
Connective tissue growth factor
Coronary Vessels
Developmental Biology
Diabetes
Diabetes mellitus
Diabetic Cardiomyopathies - drug therapy
Disease Models, Animal
Fibrosis - drug therapy
Hypoglycemic Agents - pharmacology
Hypoglycemic Agents - therapeutic use
Life Sciences
Metformin
Metformin - pharmacology
Metformin - therapeutic use
Microvasculature
Microvessels - drug effects
Original Paper
Streptozocin
Vascular Remodeling - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although metformin is widely prescribed in diabetes, its use with associated cardiac dysfunction remains debatable. In the current study, we investigated the effect of metformin on coronary microvasculature in experimental diabetic cardiomyopathy (DCM) induced by streptozotocin. Administration of metformin after induction of DCM, reversed almost all cardiomyocyte degenerative changes induced by DCM. Metformin diminished the significantly increased (p 
ISSN:1567-2379
1567-2387
DOI:10.1007/s10735-018-9801-4